What type of hematological or solid tumors does imatinib mainly treat?

Imatinib/Gleevec is a tyrosine kinase inhibitor used to treat several specific hematological malignancies and solid tumors, especially those associated with specific genetic mutations. The mechanism of action of imatinib is by inhibiting the tyrosine kinase activity ofBCR-ABL fusion protein, interfering with abnormal signaling pathways, thereby inhibiting the proliferation of cancer cells. Its treatment indications include Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and KIT (CD117)-positive gastrointestinal stromal tumor (GIST).

For chronic myelogenous leukemia (CML), imatinib is the treatment of choice. CML is a hematologic tumor associated with an abnormality in the Philadelphia chromosome. This chromosomal abnormality leads to the formation of the BCR-ABL fusion gene and drives cancer cell proliferation through tyrosine kinase activity. Imatinib can effectively control the condition of CML patients by targeting and inhibiting this kinase activity. Since the advent of imatinib, it has significantly improved the therapeutic effect of chronic myelogenous leukemia, reduced patient mortality, and greatly improved patients' quality of life.

In addition toCML, imatinib is also widely used to treat KIT-positive gastrointestinal stromal tumors (GIST). GIST is a malignant tumor originating from the gastrointestinal tract, and its tumor cells often express KIT receptors on their surface. Imatinib prevents the proliferation and migration of tumor cells by inhibiting the tyrosine kinase activity of the KIT receptor. This drug is particularly effective for patients with advanced or metastatic GIST, and can significantly delay tumor progression and improve patients' quality of life.

In addition, imatinib is also used to treat other rare tumors, such as synthetic leukemia, eosinophilic leukemia, and systemic sclerosis. Imatinib exerts a wide range of anti-tumor effects by inhibiting specific tyrosine kinases. In clinical treatment, imatinib is considered a targeted therapy drug. Because of its selective effect on tumor cells, it has relatively few side effects and is well tolerated by patients.

Reference materials:https://www.gleevec.com/